Literature DB >> 12854176

Effects of heparin on liver fibrosis in patients with chronic hepatitis B.

Jun Shi1, Jing-Hua Hao, Wan-Hua Ren, Ju-Ren Zhu.   

Abstract

AIM: To evaluate the effects of heparin on liver fibrosis in patients with chronic hepatitis B.
METHODS: Fifty-two cases under study were divided into two groups, group A and group B. The two groups were given regular treatment and heparin/low molecular weight heparin (LMWH) treatment respectively. Hepatic functions, serum hyaluronic acid (HA) and type IV collagen levels were measured before and after the treatment, and six cases were taken liver biopsy twice.
RESULTS: After treatment, hepatic functions became significantly better in both groups. Serum HA and type IV collagen levels in group B compared with group A, decreased significantly after treatment. Collagen proliferation also decreased in group B after treatment.
CONCLUSION: Heparin/LMWH can inhibit collagen proliferation in liver tissues with hepatitis B.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12854176      PMCID: PMC4615517          DOI: 10.3748/wjg.v9.i7.1611

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

Review 1.  Is liver fibrosis reversible?

Authors:  R C Benyon; J P Iredale
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

Review 2.  Advances in gene therapy of liver cirrhosis: a review.

Authors:  W J Dai; H C Jiang
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

Review 3.  Extracellular matrix degradation and the role of hepatic stellate cells.

Authors:  R C Benyon; M J Arthur
Journal:  Semin Liver Dis       Date:  2001-08       Impact factor: 6.115

Review 4.  Connective tissue biology and hepatic fibrosis: report of a conference.

Authors:  D M Bissell; S L Friedman; J J Maher; F J Roll
Journal:  Hepatology       Date:  1990-03       Impact factor: 17.425

5.  Gene expression of interstitial collagenase in both progressive and recovery phase of rat liver fibrosis induced by carbon tetrachloride.

Authors:  T Watanabe; M Niioka; S Hozawa; K Kameyama; T Hayashi; M Arai; A Ishikawa; K Maruyama; I Okazaki
Journal:  J Hepatol       Date:  2000-08       Impact factor: 25.083

6.  Endothelin stimulates transforming growth factor-beta1 and collagen synthesis in stellate cells from control but not cirrhotic rat liver.

Authors:  C R Gandhi; R H Kuddus; T Uemura; A S Rao
Journal:  Eur J Pharmacol       Date:  2000-10-20       Impact factor: 4.432

7.  Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats.

Authors:  T Nakamura; R Sakata; T Ueno; M Sata; H Ueno
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

8.  Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats.

Authors:  R Bruck; O Genina; H Aeed; R Alexiev; A Nagler; Y Avni; M Pines
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

9.  Pretelangiectasis and telangiectasis of the bovine liver: a morphological, immunohistochemical and ultrastructural study.

Authors:  P S Marcato; G Bettini; L Della Salda; M Galeotti
Journal:  J Comp Pathol       Date:  1998-08       Impact factor: 1.311

10.  Immunohistochemical study on phenotypical changes of hepatocytes in liver disease with reference to extracellular matrix composition.

Authors:  S Matsumoto; K Yamamoto; T Nagano; R Okamoto; N Ibuki; M Tagashira; T Tsuji
Journal:  Liver       Date:  1999-02
View more
  10 in total

1.  Ginkgo biloba extract reverses CCl4-induced liver fibrosis in rats.

Authors:  Yan-Jun Luo; Jie-Ping Yu; Zhao-Hong Shi; Li Wang
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

2.  Changing common sense: Anti-platelet/coagulation therapy against cirrhosis.

Authors:  Yoshihiro Ikura; Tatsuya Osuga
Journal:  World J Hepatol       Date:  2015-07-08

3.  Role of anticoagulant therapy in liver disease.

Authors:  Elisabeth P C Plompen; Jeoffrey N L Schouten; Harry L A Janssen
Journal:  Hepatol Int       Date:  2013-03-26       Impact factor: 6.047

Review 4.  The Therapeutic Potential of Anticoagulation in Organ Fibrosis.

Authors:  Hanna Oh; Hye Eun Park; Min Su Song; HaYoung Kim; Jea-Hyun Baek
Journal:  Front Med (Lausanne)       Date:  2022-05-16

5.  Antifibrotic effect of heparin on liver fibrosis model in rats.

Authors:  Binita Shah; Gaurang Shah
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-12-06

6.  Molecular Magnetic Resonance Imaging of Fibrin Deposition in the Liver as an Indicator of Tissue Injury and Inflammation.

Authors:  Iliyana Atanasova; Mozhdeh Sojoodi; Helena S Leitão; Sergei Shuvaev; Carlos F G C Geraldes; Ricard Masia; Alexander S Guimaraes; Kenneth K Tanabe; Bryan C Fuchs; Peter Caravan
Journal:  Invest Radiol       Date:  2020-04       Impact factor: 6.016

7.  Low molecular weight heparin in portal vein thrombosis of cirrhotic patients: only therapeutic purposes?

Authors:  Raffaele Licinio; Mariabeatrice Principi; Giuseppe Losurdo; Nicola Maurizio Castellaneta; Enzo Ierardi; Alfredo Di Leo
Journal:  ScientificWorldJournal       Date:  2014-12-29

Review 8.  The Role of Anticoagulation in Treating Portal Hypertension.

Authors:  Laura Turco; Filippo Schepis; Erica Villa
Journal:  Curr Hepatol Rep       Date:  2018-06-18

Review 9.  Anticoagulation in the cirrhotic patient.

Authors:  Laura Turco; Emmanuelle de Raucourt; Dominique-Charles Valla; Erica Villa
Journal:  JHEP Rep       Date:  2019-07-16

10.  Extracellular histones stimulate collagen expression in vitro and promote liver fibrogenesis in a mouse model via the TLR4-MyD88 signaling pathway.

Authors:  Zhi Wang; Zhen-Xing Cheng; Simon T Abrams; Zi-Qi Lin; E D Yates; Qian Yu; Wei-Ping Yu; Ping-Sheng Chen; Cheng-Hock Toh; Guo-Zheng Wang
Journal:  World J Gastroenterol       Date:  2020-12-21       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.